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Hepatocellular carcinoma (HCC) is a widespread disease
that develops mainly in cirrhotic liver and has a high
mortality. Treatment is multimodal and includes resection,
transplantation, transarterial chemoembolisation (TACE),
percutaneous ablation procedures (PAP), and chemother-
apy. Liver transplantation has gained a prominent role as a
treatment, although there is no uniform agreement con-
cerning which is the best approach [1].
Evidence-based medicine is lacking, as no large series or
randomized studies are available. In resectable tumors, there
is a debate between resection and liver transplantation as the
treatment of choice [2]. Liver resection has lower perioper-
ative risk, quicker recovery, and does not require
immunosuppressant therapy. In cirrhotic patients, resections
are usually limited and indicated only when the underlying
cirrhosis is compensated. However, the recurrence rate is
high. With recurrent tumors, liver transplantation has been
proposed as the therapy of last resort (salvage transplanta-
tion) [3].
When the tumor is not resectable, either for local rea-
sons (dimensions, number, and invasiveness) or the patient
has advanced cirrhosis, liver transplantation appears to be
the only potentially curative solution. The published data
support the idea that the prognosis is good enough to allow
inclusion of patients on the cadaveric waiting list if the
patient fulfills the so-called ‘‘Milan criteria’’ (single tumor
less than 5 cm in diameter or no more than three tumors,
none larger than 3 cm). United Network for Organ Sharing
has incorporated the Milan criteria in a modified staging
system for HCC that is used to allocate organs. Patients
with HCC receive 22 points, along with upgrades every 3
months [4].
Therefore, the majority of these patients will be listed for
a cadaveric organ. The initial assumption that an available
living donor will lead to a better outcome due to a shortened
waiting time has not been conclusively proven; in fact, the
recurrence rate was greater after a living donor transplan-
tation than after a deceased donor transplantation in some
studies [5]. While on the waiting list, patients can undergo
an associated procedure (TACE, PAP) in order to keep them
on the list and improve the oncological outcome. However,
a significant number of patients will be removed from the
list due to disease progression, despite the neoadjuvant
treatment, because the waiting time is quite long in most
programs. For these patients, living donor liver transplan-
tation becomes the only opportunity. On the other hand,
many patients with an HCC beyond the Milan criteria from
the beginning only have transplantation as a potential cure.
Due to this situation, an extension of the Milan criteria has
been proposed [6]. Advocates of this extension consider the
Milan criteria too restrictive, as patients with a significant
chance of a cure could be excluded from transplantation.
The most well-known extended criteria are the so-called
San Francisco criteria: single nodules up to 6.5 cm or 2–3
nodules up to 4.5 cm, with the sum of diameters not
exceeding 8 cm. Other examples of extended criteria are
those established by the Barcelona Clinic Liver Cancer
which require a single nodule less than 7 cm, 2–3 nodules
less than 5 cm, or 4–5 nodules less than 3 cm, and the 5–5
rule of M. Makuuchi (Tokyo rule) which requires no more
than five tumors, none of which may exceed 5 cm [7]. The
criteria have been extended far enough that liver trans-
plantation was proposed for all patients with no extrahepatic
disease or invasion of the main trunk of the portal vein.
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An important issue to be addressed is the fact that the
macromorphological characteristics of HCC give an
imprecise estimate of the tumor’s aggressiveness, for
which more reliable criteria could be a poorly differenti-
ated grade or microscopic vascular invasion. Recently,
even more refined criteria, such as an allelic imbalance of
microsatellites located adjacent to tumor-related genes, has
been shown to be a predictor of HCC recurrence [8]. It is
worth noting that all of these histological and molecular
criteria require tumor biopsy.
It is clear that selection criteria are necessary, no matter
how liberal the policy of a center towards liver transplan-
tation for HCC. In the absence of such criteria, the results
can be unsatisfactory, as questions arise concerning the
benefit of the method as well as the financial coverage,
particularly when treatment is assured by the state or
insurance companies.
The Mount Sinai team has already reported an increased
mortality after liver transplantation in patients with HCC
for reasons that are unclear [6]. The risk for donors is not
negligible, with mortality rates between 0.2% and 0.4%
reported at the international level for all indications of
living donor liver transplantation, and should be taken into
consideration [4]. In patients with a high MELD (Model for
End-Stage Liver Disease) score, the medical expenses can
be intolerably high [9]. Therefore, selection criteria for the
recipient remain important, even if a living donor is
available.
In a retrospective study, Sotiropoulos et al. [10] identi-
fied three individual criteria that influence the results and,
therefore, can be used as selection criteria. Age over 60
years, a MELD score above 22, and an alpha–fetoprotein
greater than 400 ng/ml were associated with a poor
prognosis.
Defining criteria that can predict the prognosis remains
an important goal as long as many centers exceed the limits
of transplantation for HCC, particularly with living donors.
The criteria defined by Sotiropoulos and collegues [10] are
useful, at least until more evidence-based medicine arising
from large randomized studies becomes available.
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